{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:18:17Z","timestamp":1761941897950,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vhri.2021.07.003","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T03:50:43Z","timestamp":1637121043000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors"],"prefix":"10.1016","volume":"28","author":[{"given":"Alexandre Hikiji","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun Wen Huey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chatree","family":"Chai-Adisaksopha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.vhri.2021.07.003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia. 2021]","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.vhri.2021.07.003_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.vhri.2021.07.003_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort","volume":"66","author":"Barg","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"10.1016\/j.vhri.2021.07.003_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2021.07.003_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.vhri.2019.03.003","article-title":"Health technology assessment and its use in drug policy in Malaysia","volume":"18","author":"Shafie","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vhri.2021.07.003_bib8","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/hae.14143","article-title":"Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea","volume":"27","author":"Lee","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.vhri.2021.07.003_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget\u00a0Impact\u00a0Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2021.07.003_bib13","first-page":"97","article-title":"Body mass index (BMI) of adults: findings of the Malaysian Adult Nutrition Survey (MANS)","volume":"15","author":"Azmi","year":"2009","journal-title":"Malays J Nutr"},{"key":"10.1016\/j.vhri.2021.07.003_bib14","unstructured":"Attorney General's Chambers of Malaysia. Federal Government Gazette: Fees (Medical) (Cost of Services) Order 2014."},{"key":"10.1016\/j.vhri.2021.07.003_bib15","unstructured":"Attorney General's Chambers of Malaysia. Federal Government Gazette: Private Healthcare Facilities and Services (Private Hospitals and Other Private Healthcare Facilities) (Amendment). Order\u00a02013."},{"issue":"4","key":"10.1016\/j.vhri.2021.07.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230850","article-title":"Rare disease in Malaysia: challenges and solutions","volume":"15","author":"Shafie","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2021.07.003_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-016-0460-9","article-title":"State of rare disease management in Southeast Asia","volume":"11","author":"Shafie","year":"2016","journal-title":"Orphanet J Rare Dis"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:50Z","timestamp":1761941570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":12,"alternative-id":["S2212109921000893"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2021.07.003","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2021.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}